Capecitabine plus paclitaxel versus epirubicin plus paclitaxel as first-line treatment for metastatic breast cancer: efficacy and safety results of a randomized, phase III trial by the AGO Breast Cancer Study Group

Lueck, Hans-Joachim; Du Bois, Andreas; Loibl, Sibylle; Schrader, Iris; Huober, Jens; Heilmann, Volker; Beckmann, Matthias; Staehler, Ann; Jackisch, Christian; Hubalek, Michael; Richter, Barbara; Stickeler, Elmar; Eidtmann, Holger; Thomssen, Christoph; Untch, Michael; Wollschlaeger, Kerstin; Schuster, Tibor; von Minckwitz, Gunter

Capecitabine plus paclitaxel versus epirubicin plus paclitaxel as first-line treatment for metastatic breast cancer: efficacy and safety results of a randomized, phase III trial by the AGO Breast Cancer Study Group

Autor(en):

Lueck, Hans-Joachim; Du Bois, Andreas; Loibl, Sibylle; Schrader, Iris; Huober, Jens; Heilmann, Volker; Beckmann, Matthias; Staehler, Ann; Jackisch, Christian; Hubalek, Michael; Richter, Barbara; Stickeler, Elmar; Eidtmann, Holger; Thomssen, Christoph; Untch, Michael; Wollschlaeger, Kerstin; Schuster, Tibor; von Minckwitz, Gunter

Tübinger Autor(en):

Huober, Jens

Erschienen in:

Breast Cancer Research and Treatment (2013), Bd. 139, H. 3, S. 779-787

Verlagsangabe:

Springer

Sprache:

Englisch

Referenz zum Volltext:

http://dx.doi.org/10.1007/s10549-013-2589-8

ISSN:

0167-6806